The approval of the first anti-tumor necrosis factor (TNF) monoclonal antibody, infliximab (IFX, Remicade®, Janssen; US in 1998, EU in 1999) radically changed treatment strategies for rheumatoid arthritis and for other chronic immune and inflammatory disorders. The gene discussed is TNF; the disease is rheumatoid arthritis.